BioCryst Pharmaceuticals (NASDAQ:BCRX) Reaches New 52-Week High - Here's What Happened

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) shares hit a new 52-week high during trading on Tuesday . The company traded as high as $9.40 and last traded at $9.36, with a volume of 600478 shares. The stock had previously closed at $9.05.

Analysts Set New Price Targets

Several research firms have recently weighed in on BCRX. Needham & Company LLC upped their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Monday, January 13th. Barclays upped their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the company an "equal weight" rating in a research report on Tuesday, November 5th. JMP Securities reissued a "market outperform" rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Finally, Evercore ISI increased their target price on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an "outperform" rating in a research report on Monday, January 13th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $15.50.

BioCryst Pharmaceuticals Price Performance

The stock has a 50 day moving average price of $8.01 and a two-hundred day moving average price of $7.84. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -15.10 and a beta of 1.75.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Large investors have recently modified their holdings of the stock. GF Fund Management CO. LTD. bought a new position in BioCryst Pharmaceuticals in the 4th quarter worth approximately $33,000. Venturi Wealth Management LLC acquired a new stake in shares of BioCryst Pharmaceuticals in the 4th quarter valued at $46,000. R Squared Ltd bought a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth $48,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company's stock valued at $57,000 after acquiring an additional 1,322 shares during the period. Finally, KBC Group NV boosted its holdings in BioCryst Pharmaceuticals by 80.1% in the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company's stock valued at $77,000 after acquiring an additional 4,537 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.